Onconova Therapeutics
Onconova Therapeutics, Inc. (Form: 8-K, Received: 05/18/2017 14:29:20)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): May 17, 2017

 


 

Onconova Therapeutics, Inc.

(Exact name of Registrant as specified in its charter)

 


 

Delaware

 

001-36020

 

22-3627252

(State or Other Jurisdiction
of Incorporation or Organization)

 

(Commission
File Number)

 

(I.R.S. Employer
Identification No.)

 

375 Pheasant Run
Newtown, PA 18940
(267) 759-3680

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

 

Not Applicable

(Former name or former address, if changed since last report)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o             Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o             Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)

 

o             Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o             Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company   x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

 

 



 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On May 17, 2017, Onconova Therapeutics, Inc. (the “Company”) held its 2017 Annual Meeting of Stockholders. At the Annual Meeting, the Company’s stockholders voted on the following proposals:

 

1. To elect the eight nominees named in the Company’s proxy statement to serve for a one-year term as a director of the Company expiring at the Company’s 2018 Annual Meeting of Stockholders and, in each case, until a successor is elected and qualified. Each nominee for director was elected by a vote of the stockholders as follows:

 

Name

 

For

 

Withheld

 

Broker Non-Votes

Henry S. Bienen

 

2,607,529

 

440,900

 

2,158,884

Jerome E. Groopman

 

2,606,369

 

442,060

 

2,158,884

Michael B. Hoffman

 

2,607,741

 

440,688

 

2,158,884

Ramesh Kumar

 

2,607,661

 

440,768

 

2,158,884

James J. Marino

 

2,606,359

 

442,070

 

2,158,884

Viren Mehta

 

2,607,641

 

440,788

 

2,158,884

E. Premkumar Reddy

 

2,607,459

 

440,970

 

2,158,884

Jack E. Stover

 

2,606,359

 

442,070

 

2,158,884

 

2. To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2017. The proposal was approved by a vote of the stockholders as follows:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

4,782,359

 

13,127

 

411,827

 

 

2



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: May 18, 2017

Onconova Therapeutics, Inc.

 

 

 

By:

/ s/ MARK GUERIN

 

 

Name: Mark Guerin

 

 

Title: Chief Financial Officer

 

3